Mitsufumi Endo
Tokyo Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mitsufumi Endo.
Cancer Research | 2005
Kazufumi Honda; Yasuharu Hayashida; Tomoko Umaki; Takuji Okusaka; Tomoo Kosuge; Satoru Kikuchi; Mitsufumi Endo; Akihiko Tsuchida; Tatsuya Aoki; Takao Itoi; Fuminori Moriyasu; Setsuo Hirohashi; Tesshi Yamada
The survival rate of pancreatic cancer patients is the lowest among those with common solid tumors, and early detection is one of the most feasible means of improving outcomes. We compared plasma proteomes between pancreatic cancer patients and sex- and age-matched healthy controls using surface-enhanced laser desorption/ionization coupled with hybrid quadrupole time-of-flight mass spectrometry. Proteomic spectra were generated from a total of 245 plasma samples obtained from two institutes. A discriminating proteomic pattern was extracted from a training cohort (71 pancreatic cancer patients and 71 healthy controls) using a support vector machine learning algorithm and was applied to two validation cohorts. We recognized a set of four mass peaks at 8,766, 17,272, 28,080, and 14,779 m/z, whose mean intensities differed significantly (Mann-Whitney U test, P < 0.01), as most accurately discriminating cancer patients from healthy controls in the training cohort [sensitivity of 97.2% (69 of 71), specificity of 94.4% (67 of 71), and area under the curve value of 0.978]. This set discriminated cancer patients in the first validation cohort with a sensitivity of 90.9% (30 of 33) and a specificity of 91.1% (41 of 45), and its discriminating capacity was further validated in an independent cohort at a second institution. When combined with CA19-9, 100% (29 of 29 patients) of pancreatic cancers, including early-stage (stages I and II) tumors, were detected. Although a multi-institutional large-scale study will be necessary to confirm clinical significance, the biomarker set identified in this study may be applicable to using plasma samples to diagnose pancreatic cancer.
Journal of Chromatography B | 2007
Tadashi Kondo; Tetsuya Okano; Kiyonaga Fujii; Kazufumi Honda; Mitsufumi Endo; Akihiko Tsuchida; Tatsuya Aoki; Takao Itoi; Fuminori Moriyasu; Tesshi Yamada; Harubumi Kato; Toshihide Nishimura; Satoru Todo; Setsuo Hirohashi
Abstract We investigated the aberrant expression of plasma proteins in patients with pancreatic cancer. High-abundance plasma proteins (albumin, transferrin, haptoglobin, alpha-1-antitrypsin, IgG and IgA) were depleted by use of an immuno-affinity column, and low-abundance ones were separated into five fractions by anion-exchange chromatography. The fractionated plasma proteins were subjected to 2D-DIGE with highly sensitive fluorescent dyes. The quantitative protein expression profiles obtained by 2D-DIGE were compared between two plasma protein mixtures: one from five non-cancer bearing healthy donors and the other from five patients with pancreatic cancer. Among 1200 protein spots, we found that 33 protein spots were differently expressed between the two mixtures; 27 of these were up-regulated and six were down-regulated in cancer. Mass spectrometry and database searching allowed the identification of the proteins corresponding to the gel spots. Up-regulation of leucine-rich alpha-2-glycoprotein (LRG), which has not previously been implicated in pancreatic cancer, was observed. Western blotting with an anti-LRG antibody validated the up-regulation of LRG in an independent series of plasma samples from healthy controls, patients with chronic pancreatitis, and patients with pancreatic cancer. Our results demonstrate the application of a combination of multi-dimensional liquid chromatography with 2D-DIGE for plasma proteomics and suggest the clinical utility of LRG plasma level measurement.
Journal of Artificial Organs | 2001
Mitsufumi Endo; Shin Enosawa; Seiichi Suzuki; Hiroshi Amemiya; Shuichi Tsuruoka; Akio Fujimura; Shinya Hiramatsu; Takeshi Omasa; Ken-ichi Suga; Toshiharu Matsumura; Tatsuya Aoki; Yasuhisa Koyanagi
To improve the present bioartificial liver systems by adding the capacity for selective and active transport, recombinant hepatic GS-HepG2 and renal proximal convoluted tubular cell line-multidrug resistant (PCTL-MDR) cell lines were cocultured on opposite sides of a expanded polytetrafluoroethylene (ePTFE) membrane, and active transport and drug metabolism were examined. PCTL-MDR formed a tight monolayer on the ePTFE membrane to block nonspecific leakage of polysaccharide, while the cells transported anionic digoxin from the membrane side to the medium side. GS-HepG2 cells showed a capacity for testosterone metabolism, and the metabolite, probably androstenedione, as well as testosterone, was transported by PCTL-MDR. The combination of hepatic and renal cell lines in the appropriate bioreactor vessel will enable bioartificial hemofiltration, which has not been achieved with the present bioartificial liver assist systems.
Oncology Reports | 2003
Akihiko Tsuchida; Kazuhiko Kasuya; Mitsufumi Endo; Hitoshi Saito; Keiichiro Inoue; Itsuro Nagae; Tasuya Aoki; Yasuhisa Koyanagi
Oncology Reports | 2003
Akihiko Tsuchida; Yuichi Nagakawa; Kazuhiko Kasuya; Takao Itoi; Mitsufumi Endo; Takashi Ozawa; Tatsuya Aoki; Yasuhisa Koyanagi
Japanese Journal of Clinical Oncology | 2001
Tatsuya Aoki; Akihiko Tsuchida; Kazuhiko Kasuya; Mitsufumi Endo; Keiichi Kitamura; Yasuhisa Koyanagi
Carcinogenesis | 2005
Akihiko Tsuchida; Takao Itoi; Kazuhiko Kasuya; Mitsufumi Endo; Kenji Katsumata; Toshiaki Aoki; Minako Suzuki; Tatsuya Aoki
Oncology Reports | 2004
Akihiko Tsuchida; Takao Itoi; Mitsufumi Endo; Keiichi Kitamura; Masahito Mukaide; Fumihide Itokawa; Takashi Ozawa; Tatsuya Aoki
Artificial Organs | 2002
Mitsufumi Endo; Shin Enosawa; Michitaka Ozaki; Shuichi Tsuruoka; Shinya Hiramatsu; Kazumi Kim; Takeshi Omasa; Toshiharu Matsumura; Tatsuya Aoki; Yasuhisa Koyanagi; Seiichi Suzuki
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2005
Yasuharu Mori; Kenji Katsumata; Asuka Harada; Mitsufumi Endo; Akihiko Tsuchida; Tatsuya Aoki